Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879744 | 0.78 | PTGER1 (1.00) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL28942410 | 0.77 | L3MBTL1 (0.43) | PTGER1KMT2ASLC6A4 | |
| SCHEMBL2111464 | 0.76 | PTGER1 (0.55) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL4883549 | 0.76 | PTGER1 (0.58) | PTGER1CYP2C9CYP3A4KMT2ALRRK2 | |
| SCHEMBL2112850 | 0.75 | PTGER1 (0.55) | PTGER1CYP2C9CYP3A4LRRK2TBXA2R | |
| SCHEMBL5096000 | 0.74 | PTGER1 (0.64) | PTGER1CYP2C9CYP3A4SLC6A4TBXA2R | |
| SCHEMBL6028879 | 0.74 | PTGER1 (0.53) | PTGER1CYP2C9CYP3A4SLC6A4TBXA2R | |
| SCHEMBL4878036 | 0.74 | PTGER1 (0.61) | PTGER1CYP2C9CYP3A4LRRK2TBXA2R | |
| SCHEMBL5271986 | 0.74 | PTGER1 (0.50) | PTGER1CYP2C9SLC6A4 | |
| SCHEMBL27650129 | 0.73 | PTGER1 (0.52) | PTGER1CYP2C9CYP3A4LRRK2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| EP-1670756-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037786-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | PTGER1 1/4885CYP2C9 820/4885CYP3A4 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.